The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy of chemotherapy, radiation therapy (RT), or both. One potential target is the ubiquitin-proteasome pathway. This pathway plays an essential role in the degradation of most short- and long-lived intracellular proteins in eukaryotic cells and therefore regulating the cell cycle, neoplastic growth, and metastasis. Bortezomib is a selective 26S proteasome inhibitor that has been approved for the treatment of multiple myeloma. Bortezomib has demonstrated in vitro chemotherapy- and RT-sensitizing properties as well as single-agent activity in lung cancer. This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC.

Original languageEnglish
Pages (from-to)S64-66
JournalClinical Lung Cancer
Volume7 Suppl 2
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.'. Together they form a unique fingerprint.

Cite this